RVMD
Income statement / Annual
Last year (2023), Revolution Medicines, Inc.'s total revenue was $11.58 M,
a decrease of 67.27% from the previous year.
In 2023, Revolution Medicines, Inc.'s net income was -$436.37 M.
See Revolution Medicines, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
| Operating Revenue |
$11.58 M
|
$35.38 M
|
$29.39 M
|
$42.98 M
|
$50.04 M
|
$20.17 M
|
$0.00
|
| Cost of Revenue |
$411.24 M |
$9.66 M |
$7.33 M |
$132.25 M |
$91.76 M |
$1.76 M |
$1.19 M |
| Gross Profit |
-$399.66 M |
$25.72 M |
$22.06 M |
-$89.27 M |
-$41.71 M |
$18.40 M |
-$1.19 M |
| Gross Profit Ratio |
-34.51 |
0.73 |
0.75 |
-2.08 |
-0.83 |
0.91 |
0 |
| Research and Development
Expenses |
$423.14 M
|
$253.07 M
|
$186.95 M
|
$132.25 M
|
$91.76 M
|
$51.08 M
|
$26.59 M
|
| General & Administrative
Expenses |
$75.62 M
|
$40.59 M
|
$30.45 M
|
$21.43 M
|
$12.41 M
|
$9.41 M
|
$4.54 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$75.62 M
|
$40.59 M
|
$30.45 M
|
$21.43 M
|
$12.41 M
|
$9.41 M
|
$4.54 M
|
| Other Expenses |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
-$2.12 M |
$0.00 |
| Operating Expenses |
$498.77 M |
$293.66 M |
$217.40 M |
$153.68 M |
$104.16 M |
$60.49 M |
$31.13 M |
| Cost And Expenses |
$498.77 M |
$293.66 M |
$217.40 M |
$153.68 M |
$104.16 M |
$60.49 M |
$31.13 M |
| Interest Income |
$47.48 M |
$9.15 M |
$929,000.00 |
$2.24 M |
$2.19 M |
$777,000.00 |
$105,000.00 |
| Interest Expense |
$303,000.00 |
$0.00 |
$12,000.00 |
$71,000.00 |
$106,000.00 |
$116,000.00 |
$103,000.00 |
| Depreciation &
Amortization |
$9.31 M
|
$9.66 M
|
$7.33 M
|
$6.55 M
|
$3.34 M
|
$1.76 M
|
$1.19 M
|
| EBITDA |
-$430.58 M
|
-$239.47 M
|
-$179.75 M
|
-$101.91 M
|
-$48.59 M
|
-$39.91 M
|
-$29.84 M
|
| EBITDA Ratio |
-37.18 |
-7.04 |
-6.37 |
-2.52 |
-0.97 |
-1.98 |
0 |
| Operating Income Ratio
|
-42.07
|
-7.3
|
-6.4
|
-2.58
|
-1.08
|
-2
|
0
|
| Total Other
Income/Expenses Net |
$47.29 M
|
$9.15 M
|
$917,000.00
|
$2.17 M
|
$2.08 M
|
-$1.46 M
|
$2,000.00
|
| Income Before Tax |
-$439.89 M |
-$249.13 M |
-$187.09 M |
-$108.53 M |
-$52.04 M |
-$41.79 M |
-$31.13 M |
| Income Before Tax Ratio
|
-37.99
|
-7.04
|
-6.37
|
-2.52
|
-1.04
|
-2.07
|
0
|
| Income Tax Expense |
-$3.52 M |
-$420,000.00 |
-$7.32 M |
-$371,000.00 |
-$4.37 M |
-$1.34 M |
$105,000.00 |
| Net Income |
-$436.37 M |
-$248.71 M |
-$179.77 M |
-$108.16 M |
-$47.66 M |
-$41.79 M |
-$31.13 M |
| Net Income Ratio |
-37.68 |
-7.03 |
-6.12 |
-2.52 |
-0.95 |
-2.07 |
0 |
| EPS |
-3.86 |
-3.08 |
-2.47 |
-1.62 |
-0.81 |
-1.15 |
-0.85 |
| EPS Diluted |
-3.86 |
-3.08 |
-2.47 |
-1.62 |
-0.81 |
-1.15 |
-0.85 |
| Weighted Average Shares
Out |
$113.15 M
|
$80.63 M
|
$72.81 M
|
$66.60 M
|
$59.00 M
|
$36.47 M
|
$36.47 M
|
| Weighted Average Shares
Out Diluted |
$113.15 M
|
$80.63 M
|
$72.81 M
|
$66.60 M
|
$59.00 M
|
$36.47 M
|
$36.47 M
|
| Link |
|
|
|
|
|
|
|
